Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Clears Out Pipeline: After Oncology Disappointments, Talks Up Diabetes

Executive Summary

Pfizer’s latest major pipeline clear-out resulted in losses of Sutent development in a number of cancers and figitumumab in non-small cell lung cancer, among many other discontinuations.

You may also be interested in...



Pfizer Touts Bosutinib Advantages, Debuts Hedgehog Inhibitor At ASH

Among its presentations at the American Society of Hematology meeting, Pfizer debuted Hedgehog Smoothen inhibitor PF-04449913, showing off encouraging Phase I monotherapy data in highly refractory patients. The drug would pair nicely with late-stage bosutinib to hit chronic myelogenous leukemia in two ways: through stem cells and through mature cells, Pfizer’s Rothenberg said.

Sutent Pancreatic Tumor Study Shows Regulatory Pitfalls Of Stopping Early

Pfizer’s development of Sutent (sunitinib) for treatment of pancreatic tumors shows the potential pitfalls sponsors face when they decide to terminate clinical trials early due to positive results.

Sutent Pancreatic Tumor Study Shows Regulatory Pitfalls Of Stopping Early

Pfizer’s development of Sutent (sunitinib) for treatment of pancreatic tumors shows the potential pitfalls sponsors face when they decide to terminate clinical trials early due to positive results.

Related Content

Topics

UsernamePublicRestriction

Register

PS052679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel